RCT | Lecanemab slows cognitive decline in early Alzheimer’s disease but raises safety concerns.
2 Dec, 2022 | 14:40h | UTCLecanemab in Early Alzheimer’s Disease – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries:
Heralded Alzheimer’s drug works — but safety concerns loom – Nature
Lecanemab and Alzheimer’s: More Data – Science
Alzheimer’s Drug is Hailed Amid Safety Concerns – Health Policy Watch
Related: Second death linked to potential antibody treatment for Alzheimer’s disease – Science
Commentary on Twitter
In a phase 3 trial, participants with early Alzheimer’s disease who received the monoclonal antibody lecanemab had less decline on measures of cognitive function at 18 months than those who received placebo. https://t.co/NjEloWVk1V pic.twitter.com/n33yjV9117
— NEJM (@NEJM) November 30, 2022